Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 10/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.53 |
| ▸ | KCNH2 known ✓ | Q12809 | 6/20 | 0.48 |
| ▸ | PNMT | P11086 | 2/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14829137 | 1.00 | PNMT (0.65) | PNMTTAAR1SIGMAR1TMEM97SLC6A2 | |
| SCHEMBL14731704 | 0.98 | PNMT (0.67) | PNMTTAAR1SIGMAR1TMEM97SLC6A2 | |
| SCHEMBL10859086 | 0.98 | PNMT (0.67) | PNMTTAAR1SIGMAR1TMEM97SLC6A2 | |
| SCHEMBL14829388 | 0.87 | PNMT (0.62) | PNMTTAAR1SIGMAR1TMEM97SLC6A2 | |
| Bromide SCHEMBL14829153 | 0.86 | PNMT (0.61) | PNMTTAAR1SIGMAR1TMEM97SLC6A2 | |
| SCHEMBL12436727 | 0.82 | SIGMAR1 (0.58) | PNMTTAAR1SIGMAR1TMEM97KCNH2 | |
| Hydrochloric Acid SCHEMBL14829304 | 0.82 | PNMT (0.52) | PNMTTAAR1SIGMAR1TMEM97KCNH2 | |
| SCHEMBL4910377 | 0.80 | PNMT (0.58) | PNMTTAAR1SIGMAR1TMEM97KCNH2 | |
| SCHEMBL15907626 | 0.80 | PNMT (0.53) | PNMTTAAR1SIGMAR1TMEM97KCNH2 | |
| SCHEMBL10603412 | 0.79 | PNMT (0.57) | PNMTTAAR1SIGMAR1TMEM97KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2760829-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9249096-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-17 | — | — | US | disclosed |
| EP-2760828-B1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9120794-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2760840-B1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-8952180-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-8946430-B2 | Quinolinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140243314-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-28 | — | — | US | disclosed |
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2760828-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2760840-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20140213588-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2013151923-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013048942-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049096-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221357-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, PNLIP | SIGMAR1 2611/4885SLC6A2 4545/4885SLC6A4 4188/4885 |
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | SIGMAR1 2062/4885SLC6A2 4220/4885SLC6A4 4052/4885 |
| US-20140243314-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | SIGMAR1 1756/4885SLC6A2 3832/4885SLC6A4 3859/4885 |
| US-20150105378-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, PNLIP, LPL | SIGMAR1 2928/4885SLC6A2 4681/4885SLC6A4 4377/4885 |
| US-20140213588-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, PNLIP, LPL | SIGMAR1 2851/4885SLC6A2 4645/4885SLC6A4 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.